Welcome to our dedicated page for CURANEX PHARMACEUTICALS SEC filings (Ticker: CURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Curanex Pharmaceuticals Inc (CURX) SEC filings page on Stock Titan provides organized access to the company’s public filings with the U.S. Securities and Exchange Commission. As a developmental-stage biotechnology company listed on the Nasdaq Capital Market, Curanex uses these documents to report on its financial condition, capital markets activities, regulatory status, and progress as it develops botanical drugs for inflammatory diseases.
Investors can review registration statements and related documents that describe Curanex’s initial public offering and the exercise of underwriters’ over-allotment options. Filings such as Form 8-K give details on unregistered sales of equity securities, related-party loans, and the repayment of promissory notes that eliminated outstanding debt and reduced future interest obligations.
Regulatory and listing matters appear in Curanex’s current reports on Form 8-K, including disclosures about a Nasdaq notice that the company’s common stock had traded below the minimum bid price required for continued listing on the Nasdaq Capital Market. These filings outline the compliance period granted to the company and potential next steps if the minimum bid price requirement is not met.
The filings page also includes documents such as Form 12b-25 (Notification of Late Filing), where Curanex explained why it could not file a Quarterly Report on Form 10-Q by the prescribed date and indicated its intention to file within the allowed extension period. Over time, investors can expect to see quarterly reports (Form 10-Q) and annual reports (Form 10-K) that provide more detailed financial statements and management discussion when available.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain complex sections in simpler language, and help users quickly identify information on topics such as capital structure, listing compliance, and development plans for the Phyto-N botanical drug candidate.
Curanex Pharmaceuticals files its annual report describing an early-stage strategy built around Phyto-N, a proprietary botanical drug candidate for inflammatory diseases. The company is still pre-revenue and remains in preclinical development.
Curanex targets a first Investigational New Drug filing for ulcerative colitis in the fourth quarter of 2026, followed by a Phase 1 trial planned in Australia. Phyto-N is being studied across six indications, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, supported by animal data and a pilot-scale GMP manufacturing batch completed in 2026.
As of March 30, 2026, the company had 28,364,812 common shares outstanding, following an initial public offering completed in 2025. Management emphasizes substantial scientific, regulatory, and financing risks before any potential commercialization.
Curanex Pharmaceuticals Inc entered into new executive employment agreements for its two top leaders. On March 2, 2026, the company signed a CEO agreement with Jun Liu, effective March 1, 2026, with a base salary of $393,600 per year and an automobile lease benefit of $3,998 per month. The agreement runs for four years and can be renewed for one-year periods by mutual consent, and includes equity incentive eligibility and standard employee benefits.
Curanex also signed a COO agreement with Dr. Liqin Xie, effective March 1, 2026, with a base salary of $180,000 per year, equity plan eligibility, and standard benefits. His employment is at will and can be ended by either side at any time. Both executives receive three months of salary, continued benefits, and immediate vesting of unvested options or restricted shares if terminated without cause, or for the CEO, if he resigns for defined good reason. The agreements include non-compete, non-solicitation, and confidentiality covenants.
Curanex Pharmaceuticals Inc. (CURX) completed its Nasdaq IPO in August 2025, raising approximately $13.24M in net proceeds, plus $2.07M from the underwriters’ over-allotment exercise. As of September 30, 2025, the company held $5,830,537 in cash and had total assets of about $14.5M, driven largely by $8.47M of prepaid R&D with CROs and CDMOs.
The business remains pre-revenue and reported a net loss of $954,059 for the quarter and $1,151,988 for the nine months ended September 30, 2025, mainly from general and administrative costs of $466,863 and R&D expenses of $679,574. Management now concludes prior going concern doubts are alleviated based on IPO funding, though the company disclosed a Nasdaq notice on November 5, 2025 for its share price being below $1.00, with a compliance period through May 4, 2026.
Curanex Pharmaceuticals (CURX) reported a Nasdaq notice that its common stock failed the $1.00 minimum bid price requirement for 30 consecutive business days. Trading on the Nasdaq Capital Market continues under “CURX”.
The company has a 180‑day compliance period until May 4, 2026 to regain compliance by having a closing bid of at least $1.00 for a minimum of ten consecutive business days (subject to Nasdaq staff discretion). If unmet, Curanex may receive an additional 180 days if it satisfies other initial listing standards and notifies Nasdaq of an intent to cure, which may include a reverse stock split. Failing that, the stock would be subject to delisting.
Curanex Pharmaceuticals Inc reported two key actions. The company issued 28,312 unregistered shares of common stock to investor Xiaohong Song under a prior subscription agreement, in exchange for $200,000 that had been subscribed contingent on its initial public offering. This share grant represents 0.1% of 28,312,500 total common shares outstanding at the time of issuance and was made under a private offering exemption.
Curanex also fully repaid two insider loans from Dian Ying Jing, the CEO’s spouse, totaling $400,000 of principal. It paid $408,537.32 in aggregate, including $8,537.32 of accrued interest at a 4.34% annual rate, and did so ahead of the 2027 maturity dates. This prepayment eliminated all of the company’s outstanding debt and removed approximately $26,182.68 of future interest charges that would have accrued through maturity.